本文選題：腹膜透析 + 癌抗原��； 參考：《上海交通大學(xué)學(xué)報(醫(yī)學(xué)版)》2016年03期

【摘要】：目的探討腹膜透析(腹透)患者透出液中癌抗原125(CA125)水平變化對患者預(yù)后的影響。方法入選2005年1月—2009年12月間在上海交通大學(xué)醫(yī)學(xué)院附屬仁濟醫(yī)院腹透中心行持續(xù)性非臥床腹透且透析12個月以上的資料完整的患者。入選患者在開始腹透時測定透出液中CA125(dCA125)濃度,腹透12個月后復(fù)測dCA125;根據(jù)dCA125變化的中位數(shù),將患者分為dCA125穩(wěn)定組和dCA125升高組;所有患者隨訪至死亡、退出腹透、轉(zhuǎn)其他中心、失訪或至研究終止日期(2014年6月30日)。采用Kaplan-Meier法比較兩組患者生存率、技術(shù)生存率以及無腹膜炎生存時間,采用Cox比例風(fēng)險模型分析與患者預(yù)后相關(guān)的獨立危險因素。結(jié)果共有111例患者入選本研究,平均年齡(53.5±14.7)歲,男性患者53例(47.7%),27例(24.3%)患者合并糖尿病。兩組患者的基線人口學(xué)資料、臨床指標等差異均無統(tǒng)計學(xué)意義。研究期間,dCA125穩(wěn)定組(n=55)患者共發(fā)生73次腹膜炎,平均腹膜炎發(fā)生率為1次/50.0病人月;dCA125升高組(n=56)患者共發(fā)生44次腹膜炎,平均腹膜炎發(fā)生率為1次/75.3病人月。dCA125穩(wěn)定組患者的無腹膜炎生存時間明顯短于dCA125升高組患者(log-rank 6.133,P=0.013)。兩組患者的長期生存率(log-rank 2.108,P=0.147)和技術(shù)生存率(log-rank 0.108,P=0.743)差異均無統(tǒng)計學(xué)意義。Cox比例風(fēng)險模型分析顯示:dCA125升高(HR 0.538,95%CI 0.296~0.979,P=0.03)是患者發(fā)生腹膜炎的獨立保護因素。結(jié)論腹透患者dCA125升高是發(fā)生腹膜炎的保護因素,而dCA125的變化與患者長期生存率、技術(shù)生存率無關(guān)。檢測dCA125水平的變化可能可預(yù)測腹透患者腹膜炎的發(fā)生。
[Abstract]:Objective to investigate the effect of cancer antigen 125 CA 125 in peritoneal dialysis (peritoneal dialysis) on prognosis. Methods from January 2005 to December 2009, patients who underwent continuous ambulatory peritoneal dialysis at Renji Hospital affiliated to Shanghai Jiaotong University Medical College and who had been undergoing dialysis for more than 12 months were enrolled. The patients were divided into stable dCA125 group and elevated dCA125 group according to the median of dCA125 changes. All the patients were followed up until death, exited peritoneal dialysis, and transferred to other centers. Lost visit or to the end of the study date (30 June 2014). The survival rate, technique survival rate and peritonitis survival time of the two groups were compared by Kaplan-Meier method. The independent risk factors associated with prognosis were analyzed by Cox proportional risk model. Results A total of 111 patients were enrolled in this study, with an average age of 53.5 鹵14.7 years. There were 53 male patients with diabetes mellitus. There was no significant difference in baseline demographic data and clinical indexes between the two groups. During the study, 73 peritonitis occurred in patients with stable dCA125) and 44 peritonitis occurred in patients with elevated dCA125 per month (mean incidence of peritonitis was 1 / 50.0 patients per month). The mean peritonitis survival time of the stable group was significantly shorter than that of the patients with elevated dCA125. The mean incidence of peritonitis was 6.133.The survival time of the stable group was significantly shorter than that of the patients with elevated dCA125. The long-term survival rate (log-rank 2.108) and the technical survival rate (log-rank 0.108 P0.743) were not significantly different between the two groups. The Cox proportional risk model analysis showed that the increase of HR 0.53895 CI 0.296 / 0.979P0.03) was an independent protective factor for peritonitis. Conclusion the elevation of dCA125 is the protective factor of peritonitis in peritoneal dialysis patients, but the change of dCA125 is not related to long term survival rate and technical survival rate. Changes in dCA125 levels may predict peritonitis in patients with peritoneal dialysis.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟醫(yī)院腎臟科上海市腹膜透析研究中心;
【分類號】：R692.5

【相似文獻】

相關(guān)期刊論文 前10條

1 鄭振光;;肺癌患者癌抗原125檢測的臨床意義[J];檢驗醫(yī)學(xué)與臨床;2008年19期

2 張曉軍;王文余;張秀芬;;肺癌患者癌抗原125檢測的臨床意義[J];檢驗醫(yī)學(xué)與臨床;2009年08期

3 劉鳳玲;;癌抗原125檢測在肺癌患者診斷中的臨床意義[J];檢驗醫(yī)學(xué)與臨床;2011年16期

4 苗愛蓮,李軍,魏曙亞,侯蓉;血清癌抗原15.3和組織多肽特異性抗原表達水平與臨床價值[J];中華檢驗醫(yī)學(xué)雜志;2002年03期

5 張宗敏;時燕萍;;150例卵巢型子宮內(nèi)膜異位癥癌抗原_(125)表達特點探析[J];遼寧中醫(yī)藥大學(xué)學(xué)報;2010年03期

6 陳淑萍;陳燕;;消化系統(tǒng)惡性腫瘤患者腫瘤標志物癌胚抗原及癌抗原19-9和癌抗原242聯(lián)檢的臨床意義[J];中國中西醫(yī)結(jié)合消化雜志;2011年01期

7 羅冰;王衛(wèi)萍;劉明杰;王艾麗;;熒光實時定量PCR檢測前列腺癌抗原3評分方法的建立[J];醫(yī)學(xué)研究生學(xué)報;2011年06期

8 李桂芳;肝病患者血清和腹水癌抗原125的檢測[J];國外醫(yī)學(xué).臨床生物化學(xué)與檢驗學(xué)分冊;1993年02期

9 劉民培，王輝，戴兵，劉放，，陳偉，馬世英，安天義;檢測粘液癌抗原診斷直腸癌[J];中國腫瘤臨床與康復(fù);1996年03期

10 楊國亮;;癌抗原50和癌抗原199聯(lián)合檢測胰腺癌的臨床應(yīng)用價值[J];中國實用醫(yī)藥;2009年12期

相關(guān)會議論文 前3條

1 程傳宇;劉秉乾;武玉東;鄒華偉;高建光;;前列腺癌抗原-1基因復(fù)制缺陷型腺病毒載體的構(gòu)建及表達[A];第十五屆全國泌尿外科學(xué)術(shù)會議論文集[C];2008年

2 陳志成;吳瓊;李輝;高媛;柳曉蘭;陳勇;高建恩;孫啟鴻;;小鼠和大鼠抗人癌抗原(Human Carcinoma Antigen,HCA)單克隆抗體的制備與鑒定[A];中國蛋白質(zhì)組學(xué)第三屆學(xué)術(shù)大會論文摘要[C];2005年

3 陳志成;吳瓊;李輝;高媛;柳曉蘭;陳勇;高建恩;孫啟鴻;;小鼠和大鼠抗人癌抗原(Human Carcinoma Antigen,HCA)單克隆抗體的制備與鑒定[A];第10屆全國實驗血液學(xué)會議論文摘要匯編[C];2005年

相關(guān)重要報紙文章 前1條

1 ;Cenzyme和Purdue合作開發(fā)癌抗原[N];中國高新技術(shù)產(chǎn)業(yè)導(dǎo)報;2001年

相關(guān)碩士學(xué)位論文 前2條

1 肖俐霞;人附睪分泌蛋白4和癌抗原125光激化學(xué)發(fā)光免疫分析試劑的研制[D];南方醫(yī)科大學(xué);2015年

2 梁宏;靶向干擾前列腺癌抗原-1表達對前列腺癌裸鼠移植瘤的影響[D];鄭州大學(xué);2012年

本文編號：1929958